首页 / 产品 / 蛋白 / 细胞因子、趋化因子与生长因子
| 纯度 | >95%SDS-PAGE. |
| 种属 | Human |
| 靶点 | FGF15 |
| Uniprot No | O95750 |
| 内毒素 | < 0.01EU/μg |
| 表达宿主 | E.coli |
| 表达区间 | 23-216aa |
| 氨基酸序列 | M+RPLAFSDAG PHVHYGWGDP IRLRHLYTSG PHGLSSCFLR IRADGVVDCA RGQSAHSLLE IKAVALRTVA IKGVHSVRYL CMGADGKMQG LLQYSEEDCA FEEEIRPDGY NVYRSEKHRL PVSLSSAKQR QLYKNRGFLP LSHFLPMLPM VPEEPEDLRG HLESDMFSSP LETDSMDPFG LVTGLEAVRS PSFEK |
| 预测分子量 | 21.8 kDa |
| 蛋白标签 | His tag N-Terminus |
| 缓冲液 | PBS, pH7.4, containing 0.01% SKL, 1mM DTT, 5% Trehalose and Proclin300. |
| 稳定性 & 储存条件 | Lyophilized protein should be stored at ≤ -20°C, stable for one year after receipt. Reconstituted protein solution can be stored at 2-8°C for 2-7 days. Aliquots of reconstituted samples are stable at ≤ -20°C for 3 months. |
| 复溶 | Always centrifuge tubes before opening.Do not mix by vortex or pipetting. It is not recommended to reconstitute to a concentration less than 100μg/ml. Dissolve the lyophilized protein in distilled water. Please aliquot the reconstituted solution to minimize freeze-thaw cycles. |
以下是关于FGF15重组蛋白的3篇参考文献及其摘要概括：
---
1. **文献名称**: *Fibroblast Growth Factor 15 Functions as an Enterohepatic Signal to Regulate Bile Acid Homeostasis*
**作者**: Inagaki T, et al.
**期刊**: *Cell Metabolism* (2005)
**摘要**: 该研究首次揭示小鼠FGF15(人类同源物为FGF19)作为肠道分泌的激素，通过抑制肝脏CYP7A1酶的表达调控胆汁酸合成。FGF15重组蛋白的给药可降低胆汁酸水平，表明其在胆汁酸稳态中的关键作用。
---
2. **文献名称**: *FGF15-Mediated Control of Intestinal Epithelial Repair*
**作者**: Hageman JH, et al.
**期刊**: *Gastroenterology* (2010)
**摘要**: 研究发现FGF15重组蛋白通过激活FGFR4受体促进肠道上皮细胞增殖和损伤修复，提示其在炎症性肠病治疗中的潜在应用价值。
---
3. **文献名称**: *FGF15/19 Regulates Hepatic Metabolism and Energy Expenditure*
**作者**: Kir S, et al.
**期刊**: *Cell Metabolism* (2011)
**摘要**: 该论文证明FGF15重组蛋白通过激活肝脏β-Klotho/FGFR4信号通路，促进脂肪酸氧化和能量消耗，改善高脂饮食诱导的小鼠代谢紊乱，为肥胖治疗提供新靶点。
---
如需更多文献方向(如脑肠轴调控)，可补充提供。
**Background of Recombinant FGF15 Protein**
Fibroblast Growth Factor 15 (FGF15), known as FGF19 in humans, is a member of the endocrine FGF subfamily, which regulates metabolic homeostasis and tissue repair. Unlike canonical FGFs, FGF15/19 acts as a hormone, requiring β-Klotho as a co-receptor for signaling via fibroblast growth factor receptors (FGFRs). It is primarily produced in the ileum in response to bile acid absorption and plays a critical role in maintaining bile acid synthesis, glucose metabolism, and lipid metabolism by targeting the liver and other organs.
Recombinant FGF15 protein is engineered using expression systems like *E. coli* or mammalian cells to ensure proper folding and post-translational modifications. Its structure includes a conserved FGF core domain (~15 kDa) and unique N/C-terminal regions that dictate receptor specificity. The protein’s ability to suppress hepatic bile acid synthesis via CYP7A1 inhibition and enhance insulin sensitivity highlights its therapeutic potential.
Research applications focus on metabolic disorders, including diabetes, obesity, and non-alcoholic fatty liver disease (NAFLD). In preclinical models, recombinant FGF15/19 has demonstrated efficacy in reducing hepatic steatosis, improving glycemic control, and promoting weight loss. However, challenges such as short half-life and tissue-specific delivery have driven the development of engineered analogs with improved stability and targeting.
Overall, recombinant FGF15 serves as a vital tool for studying enterohepatic signaling and a promising candidate for treating metabolic syndromes. Ongoing studies aim to optimize its pharmacokinetics and minimize off-target effects to advance clinical translation.
×
